66 results about "Blood stem cell" patented technology

A process for extracting hemopoietic stem cells from the placenta of healthy puerperant to create hemopoistic stem cell bank features that the mechanical, enzyme digestive and monoclonal antibody-magnetic bead method is used to extract blood stem cells from placenta, and concentrate and purify them. Its advantages are high activity and high concentration.

Blood cells of interest are readily distinguishable from other blood cells and look-a-like particles found in a blood sample by their back-scatter signature. A preferred method for differentiating platelets in a blood sample is to irradiate the cells and particles, one at a time, with a beam of radiation, and to detect back-scattered (reflected) radiation using a plurality of optical fibers to transmit the back-scattered radiation to a high-gain photodetector, e.g. a photomultiplier tube. Preferably, the back-scatter signal so obtained is combined with a second signal representing, for example, either the level of forward-scatter within a prescribed, relatively narrow angular range, or the level of side-scattered radiation, or the level of attenuation of the cell-irradiating beam caused by the presence of the irradiated cell or particle in the beam, or the electrical impedance of the irradiated cell or particle, to differentiate the cells of interest. The method and apparatus of the invention are particularly useful in differentiating platelets and basophils in a blood sample.

The present invention is directed to the expansion, preferably TVEMF-expansion, of mammalian blood stem cells in a rotating bioreactor, preferably a TVEMF-bioreactor, to compositions resulting from the expanded and TVEMF-expanded cells, and to a method of treating disease or repairing tissue with the compositions.

Novel adeno-associated virus (AAV) isolates in nucleotide and amino acid forms and uses thereof are provided. The isolates show tropism for certain target tissues, such as blood stem cells, liver, heart and joint tissue, and may be used to transduce stem cells for introduction of genes of interest into the target tissues. Discrete modified portions of the cap gene, VP1, VP2, and VP3, may be used alone or in combination in the present methods.

The invention belongs to the field of cells and in particular relates to an efficient induced pluripotent stem cell reprogramming method for blood cells. The method comprises the following steps: S1,extracting monocyte from a blood specimen, and performing selective culture with an amplification culture medium so as to obtain erythrocyte progenitor cells; S2, introducing a free carrier with at least one potentiality determinant factor into the obtained erythrocyte progenitor cells; S3, culturing the erythrocyte progenitor cells with the free carrier by using a pluripotent stem cell inductionculture medium, and performing induction in a feeding layer free system so as to obtain reprogrammed intermediate state cells; S4, after induction is completed, replacing the pluripotent stem cell induction culture medium in the step S3 by a pluripotent stem cell culture medium to maintain culture, thereby obtaining cells that potentiality determinant factor expression is vanished and expression of endogenous pluripotent genes POU5F1, NANOG, TRA-1-60 and TRA-1-81 is activated, namely the induced pluripotent stem cells. The method has the beneficial effects that pluripotent stem cells without endogenous gene components can be efficiently induced, and the method is applicable to preclinical study and clinical application.

A method of expanding blood stem cells for the repair of heart tissue and/or function, and compositions resulting from the expansion method in a rotating bioreactor. This invention also relates to a method of TVEMF-expanding blood stem cells for the repair of heart tissue and/or function, and compositions resulting from the TVEMF-expansion in the TVEMF-bioreactor.

The present invention is based on the seminal discovery that cord blood (CB) and adult bone marrow (BM) CD34+ cells can be reprogrammed to early stem cells. The invention provides the reprogramming of CB and adult bone marrow (BM) CD34+ cells from subjects without any pre-treatment. Provided are methods for reprogramming blood cells of a subject. Also provided are methods of disease modeling and methods of generating subject-specific differentiated cells. In addition, the invention provides methods of identifying an agent that alters a function of subject-specific differentiated cells as well as isolated pluripotent or multipotent stem cells reprogrammed from blood cells.

The present invention provides an apparatus and methods for expansion of hematopoietic stem cell numbers. The stem cells are cultured and differentiated cells and endogenous growth factors are removed (depleted), permitting long term culture and expansion of the stem cells. The hematopoietic stem cells are used in numerous therapeutic procedures.

The invention discloses a reagent for stabilization of blood sample cells. The reagent comprises 100 micromoles per liter of L beta-cyclodextrin, 100 micromoles per liter of disodium cromoglycate, 0.05% of potassium dichromate, 50 micromoles per liter of triflusal, 100 micromoles per liter of Terutroban, 11 millimoles per liter of sodium citrate, 1.5 millimoles per liter of theophylline, 20 micromoles per liter of dipyridamole, 0.37 millimoles per liter of adenosine, 20 millimoles per liter of glucose and 1.25 millimoles per liter of LPEG. The reagent can stabilize blood cells for at least 36h and prevent blood cell aggregation. Through the reagent, a blood sample subjected to treatment does not influence follow-up sample molecule analysis. The reagent can be widely used for blood sample molecule analysis and detection and is especially suitable for cell or molecular detection such as a microfluidic technology with strict sample cell requirements and an analysis technology platforms such as a flow cytometer with strict sample cell requirements.

A method regenerates specific tissue, preferably mesenchymal tissues like bone, fat, tendon, muscle, cartilage and marrow stroma and hematological tissue (RBC, WBC, platelets, lymphocytes, hematological stem cells (HSC), endothelial progenitor cells (EPC) etc.). A method for reconstructing, regenerating, rejuvenating or reinforcing a damaged or diseased tissue in a mammal subject, and preferably a human patient, uses a (regenerated) tissue obtained by this method.

The present invention provides a method for the collection and distribution of cord blood stem cells, particularly in order to increase the number of usable cord blood stem cells that are collected overall. By using a single collection and distribution entity that applies a uniform protocol to obtain cord blood stem cell samples at each of a plurality of different collection facilities, a greater number of samples for both private and public cord blood stem cell banks can be obtained.

The present invention is directed to the TVEMF-expansion of mammalian blood stem cells, preferably CD34+/CD38− cells, to compositions resulting from the TVEMF-expanded cells, and to a method of treating disease or repairing tissue with the compositions.

The present invention is directed to the TVEMF-expansion of mammalian blood stem cells, preferably CD34+/CD38− cells, to compositions resulting from the TVEMF-expanded cells, and to a method of treating a disease or condition or repairing tissue of skin, mouth or ear with the compositions.

A diluted cleaning solution is contacted with the inner wall surface of an immunity measuring cell every time an immunity measurement treatment of a specimen is performed. Therefore, a diluting liquid is injected in advance, then a cleaning solution is injected, whereby a diluted cleaning solution is produced in the immunity measuring cell. As a result, the inner wall surface of the immunity measuring cell is maintained in a preferable state and the interval of the routine cleanings can be prolonged.

This application relates to stem cell compositions and methods for restoring age-related tissue loss in the face and other selected areas of the body. In a first embodiment, a composition includes stem cells and hyaluronic acid as a carrier wherein the stem cells are peripheral blood stem cells, bone marrow-derived blood stem cells, or mesenchymal stem cells.

A method of diagnosis of anemia is disclosed whereby blood is withdrawn from a patient and the level of hematopoietic stem cells (HSC) in the blood are determined by detecting a cell surface protein chosen from ACE⁺, CD34⁺, CD38, CD90⁺ (thyl) and Lin⁻. Patients with low levels of HSC are treated and in particular patients whose levels have been reduced by drugs such as ACE inhibitors are treated using an intermittent treatment regimine of the invention.

The invention discloses a blood stem cell collecting device. The blood stem cell collecting device comprises a shell; an outer plate is arranged on the left side of the upper end of the shell; a shaftcoupler is arranged at the lower end of the outer plate; an electromotor is arranged at the lower end of the shaft coupler; a rotating shaft is arranged at the upper end of the outer plate; an outputshaft and a rotating shaft of the electromotor are connected through the shaft coupler; a driving wheel is arranged on the rotating shaft; a supporting base is arranged on the bottom surface of the internal part of the shell; a centrifugal cylinder body is arranged at the upper end of the supporting base; the upper end face of the centrifugal cylinder body is connected with the lower end face ofa turnplate; the upper end of the turnplate is connected with an upper rotating shaft; a driven wheel is arranged on the outer side of the upper rotating shaft; the driving wheel and the driven wheelare connected through a conveying belt. The blood stem cell collecting device is simple in structure and convenient to use and prevents the case that part of to-be-separated cell liquid is remained ina storage tank caused by the additional storage tank added in the device so as to guarantee the utilization rate of the to-be-separated cells and avoid waste caused by the case that part of the to-be-separated cell liquid is remained in the storage tank.

The present invention relates to method for human navel blood stem cell cultivation and directional differentiation to dopaminergic nerve cell, the dopaminergic nerve cell and its uses. The method comprises the following steps: a) navel chord blood stem cell culture; separating navel chord blood single-nucleus cell, then inoculating it at porous plate with cover glass, culturing at culture box of 36.5-37.5 degree, 3-8% CO2, saturated humidity, the cultured navel blood stem cell being obtained. b) dopaminergic nerve cell induction and differentiation : taking navel blood stem cell of good growth state, changing liquid when the stem cell grows for12-16 days and about 70-90% cell fuse, inducing cell with conditioned medium inductor or growth factor inductor, so dopaminergic nerve cell being obtained. The present invention can provides large dopaminergic nerve cell differentiated from navel chord blood stem cell.

The invention relates to a Chinese medicinal composition for inducing the generation of peripheral blood stem cells and a Chinese medicinal extract of the Chinese medicinal composition. The Chinese medicinal composition comprises medicinal materials in the specification, such as cinnamon bark, red paeony root, liquoric root, dried ginger, red date, Chinese angelica, astragalus and the like.